ReviewJournal of cosmetic dermatology2025
Emerging Roles of Dermal Fibroblasts in Hyperpigmentation and Hypopigmentation: A Review.
Review in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Bioprinted human skin equivalent for evaluating non-invasive monopolar radiofrequency treatment: a novel approach.Lasers in medical science · 2026Article
- Hypertrophic Versus Atrophic Photoaging in Monozygotic Twins: Insights from a Unique Vitiligo Case Report.Diagnostics (Basel, Switzerland) · 2026Article
- Curcumin-loaded nanocarriers for dermatological applications: current advances and biomedical implications.EXCLI journal · 2026Review
- Cutaneous Changes Beyond Psoriasis: The Impact of Biologic Therapies on Angiomas and Solar Lentigines.Medicina (Kaunas, Lithuania) · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSkin pigmentation disorders may increase patients' psychological burdens. Consequently, they are increasingly attracting attention. Dermal fibroblasts have been shown to regulate pigmentation by secreting soluble factors.
aimThis study aimed to summarize recent findings on the effects of dermal fibroblasts on hyperpigmentation and hypopigmentation, enabling the discovery of new therapeutic targets.
methodsPubMed was searched for literature on fibroblast factors, hyperpigmentation, and hypopigmentation, and a comprehensive summary and analysis were performed.
resultsFibroblasts secrete both cytokines that promote pigmentation, including stem cell factor (SCF) and keratinocyte growth factor (KGF), and small amounts of those that inhibit pigmentation, such as Dickkopf1 (DKK1) and transforming growth factor (TGF)-β. Fibroblast-derived extracellular matrix (ECM) can also affect melanocyte tyrosinase activity and the transfer of melanosomes. In hyperpigmentation disorders, such as melasma and solar lentigines, the secretion of pigmentation-promoting factors increases, and the activity of key enzymes in melanin production is elevated. In hypopigmentation disorders, including vitiligo, the secretion of melanogenic factors decreases while the factors that inhibit pigmentation increase. Fibroblasts may serve as a new therapeutic target, providing new insights to precisely treat pigmentary disorders.
conclusionsFibroblasts synthesize and secrete various cytokines and proteins that modify melanin synthesis and transfer through different signaling pathways, playing prominent roles in pigmentary skin disorders, such as photoaging, melasma, solar lentigo, and vitiligo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.